oxybutynin has been researched along with Diabetic Feet in 3 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Although the recommended dosing interval is 72 hours, many references discuss the use of 48-hour intervals in select patients, and no published reference recommends dosing intervals shorter than 48 hours." | 1.40 | Daily application of transdermal fentanyl patches in patients receiving hyperbaric oxygen therapy. ( Pawasauskas, J; Perdrizet, G, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, YS | 1 |
| Sung, DK | 1 |
| Kong, WH | 1 |
| Kim, H | 1 |
| Hahn, SK | 1 |
| Game, F | 1 |
| Jeffcoate, W | 1 |
| Tarnow, L | 1 |
| Jacobsen, JL | 1 |
| Whitham, DJ | 1 |
| Harrison, EF | 1 |
| Ellender, SJ | 1 |
| Fitzsimmons, D | 1 |
| Löndahl, M | 1 |
| Pawasauskas, J | 1 |
| Perdrizet, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| LeucoPatch in the Management of Hard-to-heal Diabetic Foot Ulcers[NCT02224742] | Phase 4 | 269 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| Reapplix 3C Patch® System for the Treatment of Diabetic Foot Ulcers: A Medicare Claims Study[NCT03997526] | 22 participants (Actual) | Observational | 2020-07-15 | Terminated (stopped due to CMS status changed - 3C Patch is now fully covered (NCD) - Medicare will no longer be collecting claims under CED) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for oxybutynin and Diabetic Feet
| Article | Year |
|---|---|
LeucoPatch system for the management of hard-to-heal diabetic foot ulcers in the UK, Denmark, and Sweden: an observer-masked, randomised controlled trial.
Topics: Blood Platelets; Denmark; Diabetic Foot; Drug Delivery Systems; Female; Fibrin; Humans; Leukocytes; | 2018 |
LeucoPatch system for the management of hard-to-heal diabetic foot ulcers in the UK, Denmark, and Sweden: an observer-masked, randomised controlled trial.
Topics: Blood Platelets; Denmark; Diabetic Foot; Drug Delivery Systems; Female; Fibrin; Humans; Leukocytes; | 2018 |
LeucoPatch system for the management of hard-to-heal diabetic foot ulcers in the UK, Denmark, and Sweden: an observer-masked, randomised controlled trial.
Topics: Blood Platelets; Denmark; Diabetic Foot; Drug Delivery Systems; Female; Fibrin; Humans; Leukocytes; | 2018 |
LeucoPatch system for the management of hard-to-heal diabetic foot ulcers in the UK, Denmark, and Sweden: an observer-masked, randomised controlled trial.
Topics: Blood Platelets; Denmark; Diabetic Foot; Drug Delivery Systems; Female; Fibrin; Humans; Leukocytes; | 2018 |
2 other studies available for oxybutynin and Diabetic Feet
| Article | Year |
|---|---|
Synergistic effects of hyaluronate - epidermal growth factor conjugate patch on chronic wound healing.
Topics: Administration, Topical; Animals; Cell Line; Diabetes Mellitus, Experimental; Diabetic Foot; Drug Li | 2018 |
Daily application of transdermal fentanyl patches in patients receiving hyperbaric oxygen therapy.
Topics: Aged; Analgesics, Opioid; Diabetic Foot; Female; Fentanyl; Humans; Hyperbaric Oxygenation; Middle Ag | 2014 |